Gain Therapeutics to Participate in Investment Conference
BETHESDA, Md. — Gain Therapeutics, Inc. (Nasdaq: GANX) is preparing to make a significant impression at the H.C. Wainwright 26th Annual Global Investment Conference, which will be held from September 9 to September 11, 2024. Key representatives from Gain, including Gene Mack, the Interim CEO and current CFO, along with Dr. Jonas Hannestad, the Chief Medical Officer, will be engaging in discussions and one-on-one meetings throughout the event.
Engaging with the Gain Therapeutics Team
For those interested in exploring potential collaborations or learning more about Gain Therapeutics, reaching out via email is encouraged. This conference presents a wonderful opportunity for attendees to connect directly with industry leaders, gain insights into Gain's innovative strategies, and discuss future advancements in biotechnology.
Gain Therapeutics: Innovations in Biotechnology
Gain Therapeutics, Inc. is at the forefront of biotechnology advancements, particularly in the development of allosteric therapies. Their lead candidate, GT-02287, is currently undergoing a Phase 1 clinical trial aimed at treating Parkinson’s disease, marking significant progress toward potentially transformative treatments.
Magellan™ Drug Discovery Platform
Leveraging state-of-the-art technology, Gain’s Magellan™ drug discovery platform utilizes AI-supported structural biology, proprietary algorithms, and supercomputer-powered models. This platform excels at identifying new allosteric binding sites on proteins linked to various diseases, setting Gain Therapeutics apart in the drug development arena.
Tackling Complex Health Challenges
The biotechnology sector is constantly evolving, and Gain Therapeutics is leading the charge with discoveries that could significantly reshape therapeutic landscapes. By concentrating on difficult-to-treat conditions, including neurodegenerative diseases and rare genetic disorders, Gain is dedicated to developing innovative treatments that could benefit numerous patients.
Distinctive Approach to Drug Discovery
Gain's approach incorporates machine learning tools and a comprehensive virtual compound library, enabling their team to discover and validate various small molecule hits. This innovative methodology gives Gain a competitive advantage, allowing the company to explore extensive chemical spaces and enhance their research initiatives.
Investor and Media Contacts
For additional inquiries or to connect with Gain Therapeutics, please reach out to investor contacts Apaar Jammu and Chuck Padala via their respective emails: ajammu@gaintherapeutics.com and chuck@lifesciadvisors.com. For media inquiries, Nic Johnson and Elio Ambrosio from Russo Partners can be contacted at nic.johnson@russopartnersllc.com and elio.ambrosio@russopartnersllc.com.
Frequently Asked Questions
What is Gain Therapeutics' primary focus?
Gain Therapeutics is dedicated to discovering and developing allosteric therapies aimed at treating challenging diseases, such as Parkinson’s.
Who will represent Gain Therapeutics at the conference?
The company will be represented by Gene Mack, the Interim CEO, and Dr. Jonas Hannestad, the Chief Medical Officer.
How can someone connect with Gain Therapeutics during the conference?
Individuals interested in connecting with Gain can reach out via email to arrange meetings.
What is the significance of the Magellan™ platform?
The Magellan™ platform enables Gain to identify novel allosteric binding sites, enhancing their capabilities in drug discovery.
What stage is GT-02287 currently in?
GT-02287 is currently in a Phase 1 clinical trial aimed at treating Parkinson’s disease.
